NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis $4.49 +0.02 (+0.45%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.44 -0.04 (-1.00%) As of 08/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About CARGO Therapeutics Stock (NASDAQ:CRGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CARGO Therapeutics alerts:Sign Up Key Stats Today's Range$4.45▼$4.5050-Day Range$4.10▼$4.7552-Week Range$3.00▼$25.45Volume673,476 shsAverage Volume3.18 million shsMarket Capitalization$207.03 millionP/E RatioN/ADividend YieldN/APrice Target$15.40Consensus RatingReduce Company Overview CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. Read More CARGO Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCRGX MarketRank™: CARGO Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 664th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingCARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageCARGO Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CARGO Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCARGO Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CARGO Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CRGX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCARGO Therapeutics does not currently pay a dividend.Dividend GrowthCARGO Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CRGX. News and Social Media2.8 / 5News Sentiment1.08 News SentimentCARGO Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CARGO Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows5 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of CARGO Therapeutics is held by insiders.Percentage Held by Institutions93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CARGO Therapeutics' insider trading history. Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRGX Stock News HeadlinesJefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold RatingJuly 29, 2025 | msn.comCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGXJuly 25, 2025 | businesswire.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.August 2 at 2:00 AM | The Oxford Club (Ad)URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZBJuly 25, 2025 | prnewswire.comCRGX - Cargo Therapeutics Inc Financials | MorningstarJuly 19, 2025 | morningstar.comMCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...July 11, 2025 | morningstar.comMCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 9, 2025 | seekingalpha.comCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - MorningstarJuly 9, 2025 | morningstar.comMSee More Headlines CRGX Stock Analysis - Frequently Asked Questions How have CRGX shares performed this year? CARGO Therapeutics' stock was trading at $14.42 on January 1st, 2025. Since then, CRGX shares have decreased by 68.9% and is now trading at $4.49. How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.26. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $281 million in an initial public offering on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share. Who are CARGO Therapeutics' major shareholders? Top institutional investors of CARGO Therapeutics include Public Employees Retirement System of Ohio (0.05%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan. View institutional ownership trends. How do I buy shares of CARGO Therapeutics? Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CARGO Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Price Target for CARGO Therapeutics$15.40 High Price Target$33.00 Low Price Target$4.00 Potential Upside/Downside+243.0%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.93% Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.83 per share Price / Book0.57Miscellaneous Outstanding Shares46,110,000Free Float44,764,000Market Cap$207.03 million OptionableN/A Beta0.28 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CRGX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CARGO Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.